TrialEuropean journal of drug metabolism and pharmacokinetics2023

Pharmacokinetics and Safety of Long-Acting Release Formulations of Pasireotide (SOM230) in a Male Population Who Are Hyperendemic Hepatitis B/C and Chronic Kidney Disease: An Open-Label, Phase I Study.

Chun-Jui Huang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.